Allogene Therapeutics
Ellen Johnson has a diverse work experience in the biotechnology and pharmaceutical industries. Ellen started their career as a Pharmaceutical Manufacturing Technician at Synergen in 1992. Ellen then worked as a Research Assistant in Drug Product Manufacturing before joining Amgen in 1995 as an Engineering Intern in Drug Substance Process Development. At Amgen, they progressed through various roles including Associate II in Drug Substance Manufacturing, Engineer I to III in Drug Substance Process Development, and finally as a Principal Engineer/Associate Director in Global Process Engineering. In 2015, Ellen joined GE Healthcare as a Bioprocess Solutions Architect and later became the Enterprise Solutions Technology Leader. Ellen then moved to Cytiva in 2020 as a Principal in Enterprise Solutions Technology and is currently working at Allogene Therapeutics as the Senior Director of Operations Strategy.
Ellen Johnson holds a Bachelor of Science degree from Colorado State University, where they pursued a double major in Microbiology and Biochemistry, with a minor in Chemistry. Ellen also obtained a Master of Science degree in Chemical Engineering from the same institution. The exact start and end years of their education are not provided.
This person is not in any offices
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.